权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a nanotechnology resource center to advance urological research

开发纳米技术资源中心以推进泌尿外科研究

基本信息

批准号：
10020317
负责人：
KELVIN P DAVIES
金额：
$ 33.02万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-17 至 2023-06-30
项目状态：
已结题

项目摘要

Abstract Novel technologies facilitate breakthroughs in scientific discovery with concomitant advances in therapy. In the case of nanotechnology, a major focus has been on optimizing its use for targeted drug delivery, imaging, diagnosis, or a combination of therapeutics and diagnosis (“theranosis”). However, the application of nanotechnology in the research and treatment of benign urological pathologies remains underexplored. At our institution (“Einstein”), the research laboratory of Dr. Joel Friedman has developed a nanoparticle- delivery system (the “Einstein” nanoparticle). We and others have applied this system to multiple research fields, including benign urology, as documented by >20 publications, several extramurally funded research projects, and licensing to a commercial entity. This nanoparticle-delivery system has intrinsic potential for modulation of its physicochemical properties, allowing use in a vast array of basic research and clinical conditions. However, the availability of these nanoparticle-delivery systems to the general urologic research community is currently limited by the absence of specific resource allocations for design and synthesis. This proposal addresses these limitations by establishing a P20 Resource Development Center with two primary goals: 1) to educate and promote the use of nanotechnology within the urologic basic and clinical research community, and 2) to create a resource development (research project) component in which the “Einstein” nanoparticle will be available for collaborative projects focused on benign urologic diseases. The proposed Resource Center will design and synthesize nanoparticles tailored to each research project until commercial entities assume this role. The Center will be highly synergistic, with investigators learning how nanotechnology can be applied to their specific field of research. Investigators will have access to resources and training, so they can apply the “Einstein” nanotechnology in their project. Investigators will require design and synthesis of novel nanoparticle formulations tailored to their specific research projects. This process would therefore lead to the development and expansion of novel nanoparticle formulations for a variety of benign urologic conditions. We anticipate that commercial entities will be positioned to synthesize nanoparticles within 2-4 years, eventually replacing the need for this P20 Resource Center.

抽象的新技术促进了科学发现的突破，同时也促进了治疗的进步。就纳米技术而言，主要重点是优化其在靶向药物输送、成像、诊断，或治疗与诊断的结合（“治疗诊断”）。然而，应用纳米技术在良性泌尿病理学研究和治疗中的应用仍未得到充分探索。在我们的机构（“爱因斯坦”），乔尔·弗里德曼博士的研究实验室开发了一种纳米粒子- 输送系统（“爱因斯坦”纳米粒子）。我们和其他人已经将该系统应用于多个研究领域，包括超过 20 种出版物记载的良性泌尿学、多个外部资助的研究项目、并向商业实体授予许可。这种纳米颗粒输送系统具有调节的内在潜力其理化特性使其可用于广泛的基础研究和临床条件。然而，目前，这些纳米颗粒输送系统对一般泌尿外科研究界的可用性由于缺乏设计和综合的具体资源分配而受到限制。该提案通过建立一个 P20 资源开发中心来解决这些限制，该中心由两个主要目标：1）教育和促进纳米技术在泌尿外科基础和临床领域的应用研究社区，以及 2) 创建一个资源开发（研究项目）组成部分，其中 “爱因斯坦”纳米粒子将可用于专注于良性泌尿系统疾病的合作项目。这拟议的资源中心将设计和合成适合每个研究项目的纳米粒子，直到商业实体承担这一角色。该中心将具有高度的协同作用，研究人员将学习如何将纳米技术应用于他们的具体研究领域。研究人员将可以获得资源和培训，以便他们能够应用他们的项目中的“爱因斯坦”纳米技术。研究人员需要设计和合成新型纳米粒子根据他们的具体研究项目量身定制的配方。因此，这个过程将导致发展以及针对各种良性泌尿系统疾病的新型纳米颗粒制剂的扩展。我们预计商业实体将在 2-4 年内合成纳米颗粒，最终取代需求对于这个 P20 资源中心。